Add Selexipag as Sequential Triple Combination Therapy
In this patient with severe PAH on riociguat who failed ambrisentan due to fluid retention, the next best therapy is selexipag (a prostacyclin receptor agonist), which should be added to the existing riociguat regimen to achieve sequential combination therapy. 1
Rationale for Selexipag
The 2015 ESC/ERS guidelines explicitly recommend sequential double or triple combination therapy when there is inadequate clinical response to initial therapy 1. Your patient has demonstrated inadequate response (severe PH on echo after stopping ambrisentan), making escalation to combination therapy the guideline-directed approach.
Why Selexipag Specifically:
- Prostacyclin pathway agents are the logical next step when an endothelin receptor antagonist (ERA) fails or cannot be tolerated 1, 2
- Selexipag is an oral prostacyclin receptor agonist that avoids the complexity of parenteral prostacyclin administration 2
- The combination of riociguat + prostacyclin pathway agent is supported by guidelines for sequential therapy 1
- No contraindication exists between riociguat and prostacyclin pathway agents (unlike the absolute contraindication between riociguat and PDE-5 inhibitors) 1
Alternative Endothelin Receptor Antagonists
While another ERA could theoretically be tried, this approach has significant limitations:
Consider Macitentan:
- May be better tolerated than ambrisentan regarding fluid retention
- Macitentan 10mg daily is an approved PAH therapy 2
- However, cross-intolerance between ERAs is common - your patient may develop similar edema/SOB 3
Consider Bosentan:
- Another ERA option at 125mg twice daily 2
- Same class effect concerns regarding fluid retention 3
- Real-world data shows that patients who discontinue one ERA due to side effects frequently discontinue other PAH therapies as well 4
Critical Pitfalls to Avoid
DO NOT combine riociguat with a PDE-5 inhibitor (sildenafil or tadalafil) - this combination is absolutely contraindicated 1. The guidelines explicitly state "the combination of riociguat and PDE-5i is contraindicated."
Monitoring for Fluid Retention
Since your patient developed significant edema/SOB with ambrisentan:
- Fluid retention is a class effect of ERAs, not prostacyclin pathway agents 3
- If you choose selexipag, monitor for different side effects (GI symptoms, headache, jaw pain) rather than edema
- If you choose another ERA (macitentan/bosentan), aggressive diuretic management will be essential 3
- The FDA label warns that peripheral edema requiring hospitalization can occur with ERAs 3
High-Risk Considerations
Given the severe PH on echo, assess if this patient meets high-risk criteria (WHO FC IV, elevated BNP, low cardiac index). If high-risk:
- Consider parenteral prostacyclin (IV epoprostenol) instead of oral selexipag 1
- IV epoprostenol is prioritized in high-risk patients as it has demonstrated mortality reduction 1
- Begin lung transplant evaluation if not already done 1
Practical Implementation
Starting selexipag:
- Initiate at 200 mcg twice daily
- Titrate weekly by 200 mcg increments as tolerated
- Target maximum tolerated dose up to 1,600 mcg twice daily 2
If choosing macitentan instead: